Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mezquita

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Expert Review of Respiratory Medicine|June 30, 2018
Durvalumab for the treatment of non-small cell lung cancerLaura Mezquita, David Planchard
Cancer Management and Research|February 7, 2018
The role of brigatinib in crizotinib-resistant non-small cell lung cancerLaura Mezquita, David Planchard
Future Oncology (London, England)|November 16, 2017
Durvalumab in non-small-cell lung cancer patients: current developmentsLaura Mezquita, David Planchard
Med (New York, N.Y.)|November 11, 2023
IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLCMiguel García-Pardo, Laura Mezquita
Med (New York, N.Y.)|April 13, 2024
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 studyJuan Carlos Laguna, Laura Mezquita
Expert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David Planchard
Cancers|July 24, 2021
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176Edouard Auclin, Laura Mezquita, Benjamin Besse
Revista Espanola De Salud Publica|June 11, 2013
[Development and validation of BECAD. An instrument derived from the international classification of functioning, disability and health]Micaela Moro Ipola, Laura Mezquita Guillamón
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2018
Progress in the Management of Advanced Thoracic Malignancies in 2017Roberto Ferrara, Laura Mezquita, Benjamin Besse
Bulletin Du Cancer|May 15, 2026
Radon and lung cancerEdouard Auclin, Maxime Janin, Laura Mezquita, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Expert Review of Respiratory Medicine|June 30, 2018
Durvalumab for the treatment of non-small cell lung cancerLaura Mezquita, David Planchard
Cancer Management and Research|February 7, 2018
The role of brigatinib in crizotinib-resistant non-small cell lung cancerLaura Mezquita, David Planchard
Future Oncology (London, England)|November 16, 2017
Durvalumab in non-small-cell lung cancer patients: current developmentsLaura Mezquita, David Planchard
Med (New York, N.Y.)|November 11, 2023
IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLCMiguel García-Pardo, Laura Mezquita
Med (New York, N.Y.)|April 13, 2024
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 studyJuan Carlos Laguna, Laura Mezquita
Expert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David Planchard
Cancers|July 24, 2021
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176Edouard Auclin, Laura Mezquita, Benjamin Besse
Revista Espanola De Salud Publica|June 11, 2013
[Development and validation of BECAD. An instrument derived from the international classification of functioning, disability and health]Micaela Moro Ipola, Laura Mezquita Guillamón
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2018
Progress in the Management of Advanced Thoracic Malignancies in 2017Roberto Ferrara, Laura Mezquita, Benjamin Besse
Bulletin Du Cancer|May 15, 2026
Radon and lung cancerEdouard Auclin, Maxime Janin, Laura Mezquita, et al.
Pageof 18